Whittier Trust Co. of Nevada Inc. Buys 13,904 Shares of Thermo Fisher Scientific Inc. $TMO

25 Jan 2026, 08:18 by Teresa Graham · The Cerbat Gem

Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 33.3% during the third quarter, Holdings Channel reports. The firm owned 55,663 shares of the medical research company’s stock after purchasing an additional 13,904 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Thermo Fisher Scientific were worth $26,998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. American National Bank & Trust grew its position in shares of Thermo Fisher Scientific by 74.1% during the 2nd quarter. American National Bank & Trust now owns 249 shares of the medical research company’s stock valued at $101,000 after acquiring an additional 106 shares during the period. Patton Fund Management Inc. bought a new position in Thermo Fisher Scientific in the 2nd quarter worth $210,000. Finally, Cove Private Wealth LLC grew its holdings in Thermo Fisher Scientific by 8.4% during the second quarter. Cove Private Wealth LLC now owns 3,886 shares of the medical research company’s stock valued at $1,576,000 after purchasing an additional 300 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Marc N. Casper sold 7,250 shares of the stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president owned 18,731 shares in the company, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 131,767 shares of company stock worth $76,467,793. 0.33% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on TMO. Stifel Nicolaus boosted their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Barclays increased their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Leerink Partners increased their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $625.47.

Check Out Our Latest Research Report on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $625.42 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The stock has a 50 day moving average of $590.88 and a 200 day moving average of $531.60. The firm has a market cap of $234.98 billion, a PE ratio of 36.13, a PEG ratio of 4.12 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the prior year, the firm earned $5.28 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.